Health
STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions
Publication: STAT
Author: Elaine Chen
Source published: 16/11/2026, 13:07:47 UTC
Briefing created: 16/11/2026, 13:30:08 UTC
Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 16/11/2026, 13:21:24 UTC.
Briefings
A Phase 3 trial involving Helus Pharma's psychedelic drug candidate showed significant depression reduction in major depression patients compared to placebo, with effects lasting up to 12 weeks. However, serious adverse events emerged during the study, prompting safety concerns. The study utilized a MADRS scale where the treatment group achieved a 19.5-point reduction at six weeks versus 11.9-point reduction in the placebo group, with effects maintained at 12 weeks.
Key points
- Phase 3 trial showed significant depression reduction in patients taking Helus Pharma's drug compared to placebo.
- Treatment group achieved 19.5-point MADRS reduction at six weeks versus 11.9-point reduction in placebo group.
Context
Helus Pharma reported a Phase 3 trial where their psychedelic drug candidate significantly helped people with major depression, showing effects maintained through 12 weeks. The study used a MADRS scale to measure depression reduction, with the treatment group showing superior outcomes compared to the placebo group.
Limitations
Serious adverse events emerged during the study, raising safety concerns. The evidence is limited to the Phase 3 trial results and does not include long-term follow-up data or broader population safety assessments.
Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 16/11/2026, 13:30:08 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.
View archived briefing on IPFS
bafybeify7xcjladhqd7xmudyvfpb5mzoefxrlcdy4fbbhys647pgn37ftq